Tumor necrosis factor blockade and the risk of viral infection - PubMed (original) (raw)
Review
Tumor necrosis factor blockade and the risk of viral infection
Seo Young Kim et al. Nat Rev Rheumatol. 2010 Mar.
Abstract
Tumor necrosis factor (TNF) blockers are widely used to treat rheumatoid arthritis and other chronic inflammatory diseases. Many studies have demonstrated an increased risk of opportunistic infections such as tuberculosis and fungal infection in patients treated with TNF blockers, which is thought to be related to the primary role of TNF both in host defense and in the immune response. Little is known, however, about the association between TNF blockade and the development of viral infection. Owing to the critical role of TNF in the control of viral infection, depletion of this cytokine with TNF blockers could facilitate the development or reactivation of viral infection. A number of large observational studies have found an increased risk of herpes zoster in patients receiving TNF blockers for the treatment of rheumatoid arthritis. This Review draws attention to the risk of several viral infections, including HIV, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, and human papillomavirus, in patients receiving TNF-blocking therapy for chronic inflammatory conditions. In addition, implications for clinical practice and possible preventative approaches are discussed.
Similar articles
- Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Strangfeld A, et al. JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146. JAMA. 2009. PMID: 19224750 - [Non tuberculous anti-TNF associated opportunistic infections].
Marie I, Guglielmino E. Marie I, et al. Rev Med Interne. 2010 May;31(5):353-60. doi: 10.1016/j.revmed.2009.04.010. Epub 2010 Apr 8. Rev Med Interne. 2010. PMID: 20381217 French. - Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Lan JL, et al. Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29. Ann Rheum Dis. 2011. PMID: 21719446 - [The pulmonological manifestations of rheumatoid arthritis].
Bernscherer G, Karabélyos C, Tarján Z. Bernscherer G, et al. Orv Hetil. 2008 Jul 20;149(29):1355-61. doi: 10.1556/OH.2008.28385. Orv Hetil. 2008. PMID: 18617467 Review. Hungarian. - Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Shale MJ, et al. Aliment Pharmacol Ther. 2010 Jan;31(1):20-34. doi: 10.1111/j.1365-2036.2009.04112.x. Aliment Pharmacol Ther. 2010. PMID: 19681818 Review.
Cited by
- Novel Fermentates Can Enhance Key Immune Responses Associated with Viral Immunity.
Finnegan D, Mechoud MA, FitzGerald JA, Beresford T, Mathur H, Cotter PD, Loscher C. Finnegan D, et al. Nutrients. 2024 Apr 19;16(8):1212. doi: 10.3390/nu16081212. Nutrients. 2024. PMID: 38674902 Free PMC article. - Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives.
Khoo A, Boyer M, Jafri Z, Makeham T, Pham T, Khachigian LM, Floros P, Dowling E, Fedder K, Shonka D Jr, Garneau J, O'Meara CH. Khoo A, et al. Int J Mol Sci. 2024 Feb 28;25(5):2798. doi: 10.3390/ijms25052798. Int J Mol Sci. 2024. PMID: 38474047 Free PMC article. Review. - Cellular heterogeneity in TNF/TNFR1 signalling: live cell imaging of cell fate decisions in single cells.
Preedy MK, White MRH, Tergaonkar V. Preedy MK, et al. Cell Death Dis. 2024 Mar 11;15(3):202. doi: 10.1038/s41419-024-06559-z. Cell Death Dis. 2024. PMID: 38467621 Free PMC article. Review. - Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series.
Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK. Gil A, et al. Brain Behav Immun Health. 2023 Dec 27;36:100720. doi: 10.1016/j.bbih.2023.100720. eCollection 2024 Mar. Brain Behav Immun Health. 2023. PMID: 38327880 Free PMC article. - Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV® Active Ingredients.
Jacques C, Marchand F, Chatelais M, Brulefert A, Floris I. Jacques C, et al. Life (Basel). 2024 Jan 9;14(1):102. doi: 10.3390/life14010102. Life (Basel). 2024. PMID: 38255717 Free PMC article.
References
- Furst D. The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis. Semin Arthritis Rheum 2008 Dec 29. 2008 Epub ahead of print. - PubMed
- Dixon W, Watson K, Lunt M, H KL, Silman A, Symmons D. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368–76. - PubMed
- Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 AR055885-02/AR/NIAMS NIH HHS/United States
- P60 AR047782/AR/NIAMS NIH HHS/United States
- R21 DE018750/DE/NIDCR NIH HHS/United States
- T32 AR055885/AR/NIAMS NIH HHS/United States
- K24 AR055989/AR/NIAMS NIH HHS/United States
- R01 AR056215/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical